5RXN
 
 | |
4RXN
 
 | |
1FX1
 
 | |
5UPJ
 
 | HIV-2 PROTEASE/U99283 COMPLEX | Descriptor: | 5,6,7,8,9,10-HEXAHYDRO-4-HYDROXY-3-(1-PHENYLPROPYL)CYCLOOCTA[B]PYRAN-2-ONE, HIV-2 PROTEASE | Authors: | Watenpaugh, K.D, Mulichak, A.M, Finzel, B.C. | Deposit date: | 1996-12-10 | Release date: | 1997-04-21 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2.3 Å) | Cite: | Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors. J.Med.Chem., 38, 1995
|
|
6UPJ
 
 | HIV-2 PROTEASE/U99294 COMPLEX | Descriptor: | 6,7,8,9-TETRAHYDRO-4-HYDROXY-3-(1-PHENYLPROPYL)CYCLOHEPTA[B]PYRAN-2-ONE, HIV-2 PROTEASE | Authors: | Watenpaugh, K.D, Mulichak, A.M, Finzel, B.C. | Deposit date: | 1996-12-10 | Release date: | 1997-04-21 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2.34 Å) | Cite: | Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors. J.Med.Chem., 38, 1995
|
|
7UPJ
 
 | HIV-1 PROTEASE/U101935 COMPLEX | Descriptor: | HIV-1 PROTEASE, N-(3-CYCLOPROPYL(5,6,7,8,9,10-HEXAHYDRO-2-OXO-2H-CYCLOOCTA[B]PYRAN-3-YL)METHYL)PHENYLBENZENSULFONAMIDE | Authors: | Watenpaugh, K.D, Janakiraman, M.N. | Deposit date: | 1996-12-05 | Release date: | 1997-04-21 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones. J.Med.Chem., 40, 1997
|
|
3UPJ
 
 | |
4UPJ
 
 | |
1HPO
 
 | HIV-1 PROTEASE TRIPLE MUTANT/U103265 COMPLEX | Descriptor: | 4-CYANO-N-(3-CYCLOPROPYL(5,6,7,8,9,10-HEXAHYDRO-4-HYDROXY-2-OXO-CYCLOOCTA[B]PYRAN-3-YL)METHYL)PHENYL BENZENSULFONAMIDE, HIV-1 PROTEASE | Authors: | Watenpaugh, K.D, Janakiraman, M.N. | Deposit date: | 1996-12-10 | Release date: | 1997-04-21 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2.5 Å) | Cite: | Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones. J.Med.Chem., 40, 1997
|
|
1JSV
 
 | |
1UPJ
 
 | |
2UPJ
 
 | |
1QB0
 
 | HUMAN CDC25B CATALYTIC DOMAIN | Descriptor: | BETA-MERCAPTOETHANOL, CHLORIDE ION, PROTEIN (M-PHASE INDUCER PHOSPHATASE 2 (CDC25B)), ... | Authors: | Watenpaugh, K.D, Reynolds, R.A. | Deposit date: | 1999-04-29 | Release date: | 2000-04-29 | Last modified: | 2025-03-26 | Method: | X-RAY DIFFRACTION (1.91 Å) | Cite: | Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. J.Mol.Biol., 293, 1999
|
|
1CWT
 
 | HUMAN CDC25B CATALYTIC DOMAIN WITH METHYL MERCURY | Descriptor: | CDC25 B-TYPE TYROSINE PHOSPHATASE, CHLORIDE ION, METHYL MERCURY ION, ... | Authors: | Watenpaugh, K.D, Reynolds, R.A. | Deposit date: | 1999-08-26 | Release date: | 2000-08-30 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2.3 Å) | Cite: | Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. J.Mol.Biol., 293, 1999
|
|
1CWR
 
 | |
1D4S
 
 | HIV-1 PROTEASE V82F/I84V DOUBLE MUTANT/TIPRANAVIR COMPLEX | Descriptor: | N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE, PROTEIN (HIV-1 PROTEASE) | Authors: | Watenpaugh, K.D, Janakiraman, M.N. | Deposit date: | 1999-10-05 | Release date: | 1999-10-12 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2.5 Å) | Cite: | Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J.Med.Chem., 39, 1996
|
|
1CWS
 
 | HUMAN CDC25B CATALYTIC DOMAIN WITH TUNGSTATE | Descriptor: | BETA-MERCAPTOETHANOL, CDC25 B-TYPE TYROSINE PHOSPHATASE, CHLORIDE ION, ... | Authors: | Watenpaugh, K.D, Reynolds, R.A, Chidester, C.G. | Deposit date: | 1999-08-26 | Release date: | 2000-08-30 | Last modified: | 2025-03-26 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. J.Mol.Biol., 293, 1999
|
|
1D4Y
 
 | HIV-1 PROTEASE TRIPLE MUTANT/TIPRANAVIR COMPLEX | Descriptor: | N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE, PROTEIN (HIV-1 PROTEASE) | Authors: | Watenpaugh, K.D, Janakiraman, M.N. | Deposit date: | 1999-10-06 | Release date: | 1999-10-13 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (1.97 Å) | Cite: | Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J.Med.Chem., 39, 1996
|
|
5FX2
 
 | |
4FX2
 
 | |
3FX2
 
 | |
2FX2
 
 | |
2HPE
 
 | |
2HPF
 
 | |
1I1B
 
 | |